Estos síntomas pueden ser causados por infección, lesiones, cirugía, catéter, u otras condiciones que irriten la vejiga
High levels can interfere with the ability of the blood to carry Oxygen causing headache, fatigue, dizziness, and a blue color to the skin and lips (methemoglobinemia)
, oxybutynin), by phenazopyridine hydrochloride, which has an analgesic effect on the bladder mucosa, and by analgesics
Signs and symptoms of toxicity: Clinical signs and symptoms of toxicity include blue or purple gums or skin, shortness of breath Serious side effects have been reported with phenazopyridine including the following: Yellowing of skin or eyes
Sudden decrease in amount of urine
Children—The dose is based on body weight and must be determined by your doctor
Condition
22 During a pharmacokinetic study, 90% of a daily 600 mg oral dose of phenazopyridine hydrochloride was found to be excreted within 1 day, Phenazopyridine Hydrochloride is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity in experimental animals (IARC 1980, 1982, 1987, NCI 1978)
Category: HUMAN PRESCRIPTION DRUG LABEL
, phenazopyridine is available only with your doctor's prescription
Signs of liver problems like dark urine, tiredness, decreased appetite, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes
Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the
Adult: Symptomatic relief of pain, burning, urgency, frequency, and other discomforts that arise from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters: As phenazopyridine hydrochloride: 200 mg tid
When using this
Cancer: 01/01/1988 Basis for Listing State's Qualified Experts If you have any questions, comments, or concerns about the content of this page, please contact us
phenazopyridine hydrochloride fo conducter th Carcinogenesie d s Testing Program, o Divisio Cancef rn an Caus Preventiond e , National Cancer Institut (NCI) Nationae, l Institute of Healths , high-dose 8/35) I